The Conversation (0)
GeoVax Labs announced its financial results for the third quarter of 2017.
GeoVax Labs (OTCQB:GOVX) announced its financial results for the third quarter of 2017.
As quoted in the press release:
Vaccine Development Update:
Continued Validation of MVA-VLP Vaccine Platform – GeoVax’s product pipeline is based on its Modified Vaccine Ankara (MVA) Virus-Like Particle (VLP) vaccine platform. This platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control target infections.
As discussed in more detail below, the Company’s original application of its technology was in developing preventive HIV vaccines. More recently it expanded to preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers.
Click here to read the full press release.
Source: www.marketwired.com